brentuximab vedotin (SGN-35)(Seagen / Takeda)은 Hodgkin's Lymphoma 표적 ADC로, Hodgkin's Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 64% (ClinicalTrials.gov NCT01909934). 차별점: Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic.
Hodgkin's Lymphoma
Hodgkin's Lymphoma
Active
ADCs) increased the antitumor effect of mAbs
vedotin-containing regimen versus standard chem
linker, or payload that have limited their development
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
T-cell accessibility to tumor cells, leading to improved T-cell activation
payload that have limited their development
biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic
resistance mechanisms and improving outcomes in relapsed or refractory disease
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
brentuximab vedotin (SGN-35)(Seagen / Takeda)은 Hodgkin's Lymphoma 표적 ADC로, Hodgkin's Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 64% (ClinicalTrials.gov NCT01909934). 차별점: Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic.
Hodgkin's Lymphoma
Hodgkin's Lymphoma
Active
ADCs) increased the antitumor effect of mAbs
vedotin-containing regimen versus standard chem
linker, or payload that have limited their development
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
T-cell accessibility to tumor cells, leading to improved T-cell activation
payload that have limited their development
biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic
resistance mechanisms and improving outcomes in relapsed or refractory disease
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.